Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01TDY
|
|||
| Former ID |
DIB016621
|
|||
| Drug Name |
Unacylated ghrelin
|
|||
| Synonyms |
AZP-01; Diabetes therapeutic peptide, Theratechnologies; TH-0332; Un-octanoylated ghrelin; Unacylated ghrelin (diabetes); Ghrelin inhibitor peptides (diabetes), Theratechnologies; UAG (diabetes), Alize Pharma; Unacylated ghrelin (diabetes), Alize Pharma; Unacylated ghrelin (diabetes), Theratechnologies; Un-octanoylated ghrelin (diabetes), Alize Pharma; Unacylated ghrelin (diabetes), Alize Pharma/Eli Lilly
Click to Show/Hide
|
|||
| Indication | Type-1 diabetes [ICD-11: 5A10; ICD-9: 250] | Phase 1 | [1] | |
| Company |
Theratechnologies Inc
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Ghrelin (GHRL) | Target Info | Inhibitor | [2] |
| KEGG Pathway | cAMP signaling pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Alize Pharma announces positive results for AZP-531, its unacylated ghrelin analog, from two Phase I clinical trials in healthy volunteers and obese subjects. Lyon, France, December 10, 2014. | |||
| REF 2 | Alize Pharma signs research collaboration and license option agreement with Lilly. Lyon, France, January 25, 2010. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.